Australia has achieved a global first with the development of an mRNA vaccine for foot-and-mouth disease (FMD), a highly contagious virus that affects cattle, sheep, goats, and pigs. The breakthrough, led by the Minns Labor Government in partnership with international biotechnology company Tiba BioTech, positions the nation among a small group with the capacity to produce its own FMD vaccine — a major step in protecting livestock, food supply, and trade.
Strengthening Biosecurity
While Australia remains free of FMD, an outbreak could cost the economy up to $80 billion, disrupt meat and dairy supply chains, and threaten export markets. The new vaccine is part of a $1 billion biosecurity plan to safeguard the $8 billion livestock industry and ensure national food security.
FMD is still widespread in parts of Africa, Asia, and the Middle East, with outbreaks capable of halting trade and devastating rural economies. By producing its own vaccine domestically, Australia can respond more quickly and effectively if the disease ever reaches its shores.
Faster, Safer, and Easier to Deploy
The vaccine is fully synthetic and made without infectious materials, allowing for faster, safer production. Its mRNA technology enables rapid manufacturing in an outbreak scenario, and unlike many mRNA vaccines, it can be stored long term in standard refrigeration or kept at room temperature for up to a month — making it highly practical for livestock use.
Overseas trials showed promising results, with vaccinated cattle not contracting the disease or spreading it to others. This ability to prevent virus shedding is critical for stopping outbreaks quickly.
Rapid Development and Path to Approval
The vaccine was developed in under 18 months at a cost of $2.5 million, as part of a $20 million project funded by Meat & Livestock Australia (MLA) and the NSW Government. Key partners include the NSW Department of Primary Industries, UNSW’s RNA Institute, and Germany’s Friedrich-Loeffler Institut.
It is now undergoing further testing to meet Australian Pesticides and Veterinary Medicines Authority (APVMA) standards, which would allow it to be approved for emergency use in the event of an outbreak.
Potential Impact Beyond Australia — Including North America
Although designed for Australian use, this vaccine could have far-reaching benefits. Countries such as Canada and the United States — both currently FMD-free — face similar risks. An outbreak in North America could severely disrupt meat and dairy production, impact exports, and require swift containment. A proven, rapidly producible mRNA vaccine would offer these nations a valuable tool for protecting livestock industries and maintaining market stability.
If approved, Australia’s FMD vaccine could set a new global standard for outbreak preparedness — safeguarding animal health, protecting trade, and ensuring food security at home and abroad.
